tbuckley/cabot-search huggingface dataset:
ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study
Authors: Tomoki Naoe, Toru Sakura, Yukio Kobayashi, Kensuke Usuki, Toshihiro Miyamoto, Hiroatsu Iida, Satoshi Morita, Erkut Bahceci, Masahito Kaneko, Shunsuke Yamada, Shigeru Takeshita, Shuichi Miyawaki
Journal: Blood (2015)
The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo
Authors: Yang Yang, Joseph P. Ritchie, Telisha Swain, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson
Journal: Blood (2008)
Urothelial cancer: Impact of gender on stage at diagnosis and survival.
Authors: Jeanne Michelle du Manoir, Suzanne Richter, Srikala S. Sridhar
Journal: Journal of Clinical Oncology (2012)

316 Background: Gender differences for disease course and survival in various cancers exist. Gender disparity for both stage at diagnosis and overall survival (OS) has been observed in urothelial cancer (UC). We report a single institution analysis of UC patients treated with chemotherapy to further investigate gender differences in outcomes. Methods: We identified 198 bladder cancer pts treated with chemotherapy since 2002. Chemotherapy was either given as adjuvant or palliative and the most common regimens used were gemcitabine and cisplatin, gemcitabine and carboplatin or gemcitabine alone. Age and stage at diagnosis, sex, smoking status, radiation exposures, bloodwork as a measure of organ dysfunction and overall survival info was collected. Outcomes were compared using Chi Square Statistic. Results: Age at diagnosis, smoking status and prior pelvic radiation were not significantly different (females 66.1 yrs vs males 63.6 yrs; 54% smokers in both groups; 8.3% females vs 7.6% males exposed to radiation). Significantly more females were diagnosed with advanced disease than men (70.8% vs 58.7%, p=0.049) vs earlier stages (stage 0-I) (12.2% vs 35.9%, p=0.03). For patients deceased, OS was not significantly different between genders when analysed for all stages combined (deceased 41.5 vs 39.9 mos), or for those diagnosed only at Stage IV (deceased 12.4 vs 8.6 mos). Of patients still alive at time of review, a survival advantage was apparent for men at all stages (54.8 vs 38.7 months), as well as with stage IV disease (35.9 vs 19.7 months). Gemcitabine-cisplatin was given more often to men with stage IV disease than females (93% vs 63%, p&lt;0.02) despite no difference in organ dysfunction, or ECOG performance status in females. Conclusions: We observed that while both genders are similar with respect to age at UC diagnosis, risk factors exposures (smoking, radiation) and pathological variants, females were diagnosed at later stages, and receive standard first line therapy less often. Our data suggest that this impacts negatively on OS in females diagnosed in earlier disease stages. Further research is needed to identify if we can improve outcome by promoting earlier diagnosis and more aggressive management in earlier disease in females.
The C677T Methylenetetrahydrofolate Reductase Polymorphism and Insulin Resistance in Childhood Cancer Survivors.
Authors: Lisa Ann Bishop, Lyn M Steffen, Alex Tsai, Naomi Hanson, K. Scott Baker, Donald R. Dengel, Aaron Kelly, Alan R. Sinaiko, Anna Petryk, Antoinette Moran, Joanna Lee Perkins, Jill Lundsford-Lee, Julia Steinberger
Journal: Blood (2009)
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Authors: Stephen J Luen, Roberto Salgado, Stephen Fox, Peter Savas, Jennifer Eng-Wong, Emma Clark, Astrid Kiermaier, Sandra M Swain, Jose Baselga, Stefan Michiels, Sherene Loi
Journal: The Lancet Oncology (2016)
Weight Loss Randomized Intervention Trials in Female Cancer Survivors
Authors: Rowan T. Chlebowski, Marina M. Reeves
Journal: Journal of Clinical Oncology (2016)

Purpose Observational study evidence has associated overweight/obesity with decreased survival in women with breast cancer and with several other cancers. Although full-scale, definitive weight loss adjuvant intervention trials with cancer end points remain to be conducted, a number of randomized controlled trials have evaluated weight loss interventions in survivors of cancer in women. Findings from these trials in breast, endometrial, and ovarian cancer are reviewed. Methods A systematic review of randomized controlled clinical trials evaluating weight loss interventions was updated (for studies published 2013 to 2016), and clinical trials registers were searched for ongoing trials. Results Six new randomized trials in breast cancer survivors and two randomized trials in endometrial cancer survivors were identified. Evidence from these trials and the 10 earlier randomized trials in female cancer survivors provide support for the feasibility of recruiting women closer to the cancer diagnosis and efficacy for achieving weight loss, in particular with telephone-based interventions, and have identified the challenge of achieving significant weight loss in African American cancer survivors and of maintaining weight loss in any cancer survivor group. Seven ongoing randomized trials are evaluating the influence of weight loss interventions on cancer end points (five in breast cancer, one in ovarian cancer, and one in endometrial cancer). Conclusion After a decade of preliminary studies, ongoing randomized, controlled clinical trials will potentially provide definitive assessment of whether weight loss can improve breast cancer clinical outcome. Longer-term interventions (&gt; 2 years’ duration) may be needed to optimize weight loss maintenance and any potential benefits on cancer end points.
Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma
Authors: Wenming Chen, Peng Wei, Shifang Yang, Xiangjun Zheng, Lugui Qiu, Jian Hou, Xuejun Zhang, Zhao Wang, Xiaoyan Ke, Ling Pan, Hongyan Pang
Journal: Blood (2014)
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study
Authors: Ayalew Tefferi, Elisa Rumi, Guido Finazzi, Alessandro M. Vannucchi, Maria Luigia Randi, Ilaria Nichele, Heinz Gisslinger, Rakhee Vaidya, Mario Cazzola, Alessandro Rambaldi, Lisa Pieri, Francesco Rodeghiero, Irene Bertozzi, Bettina Gisslinger, Animesh Pardanani, Juergen Thiele, Francesco Passamonti, Tiziano Barbui
Journal: Blood (2011)
Modeling Monogenic Human Nephrotic Syndrome in the Drosophila Garland Cell Nephrocyte
Authors: Tobias Hermle, Daniela A. Braun, Martin Helmstädter, Tobias B. Huber, Friedhelm Hildebrandt
Journal: Journal of the American Society of Nephrology (2016)

Steroid-resistant nephrotic syndrome is characterized by podocyte dysfunction.
Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer.
Authors: L. Militello, P. Carli, S. Spazzapan, C. Lestuzzi, G. Miolo, S. Scalone, A. Veronesi, D. Crivellari
Journal: Journal of Clinical Oncology (2011)

282 Background: T is a mainstay in adjuvant therapy for HER2+ breast cancer (BC) patients (pts). Safety and efficacy of T in elderly patients are largely unknown. In HERA trial, NSABP B-31, NCCTG N9831 only 16% of pts were older than 60 years. Risk factors for T related cardiotoxicity are age (&gt;50 y/o), hypertension, baseline LVEF (left ventricular ejection fraction &lt;55%), previous antracycline therapy and BMI. Methods: Charts of pts &gt;65 y/o with early HER2+ BC treated with T as adjuvant or neoadjuvant therapy at our institution were retrospectively reviewed. Primary endpoint was the evaluation of T cardiac toxicity and safety. Results: 22 elderly out of 172 pts (12%) were identified: 19 pts were treated only with surgery and adjuvant chemotherapy with concomitant or sequential T, 3 more pts also received neoadjuvant chemotherapy concomitant with T. According to Balducci’s criteria, fit, vulnerable and frail pts were 20, 2, 0 respectively. Median age was 69 y/o (range 65-76). Hormonal status was negative in 10/22 (45%). 21/22 were histologic grade 3. Median follow-up was 33 months. Baseline comorbidities were the following: hypertension (G2-3) in 17 pts, diabetes mellitus in 1, supra/infraventricular arrhythmia (G1-2) in 3 and 1 pts. Antracyclines were administered in 16 pts (liposomal-doxorubicin in 5 pts), a sequential taxane-regimen was used in 3 more pts. Neoadjuvant weekly Paclitaxel and concomitant T was used in 3 pts. Median basal LVEF was 65% (range 59-74%). 2 pts developed an asymptomatic 10% LVEF drop from baseline (left ventricular systolic dysfunction G1) during T treatment. Known cardiac risk factors were hypertension in 1 pt and previous antracycline based chemotherapy in both. They recovered within 9 months. One minor adverse event was atrial fibrillation (G2) during T treatment. Conclusions: T was well tolerated in elderly pts. More data are needed in order to understand the correlations between T related toxicity and cardiovascular risk factors. Long term safety of T treatment should verify the reversibility of cardiac T related toxicity on elderly pts.
Long Term Follow-Up of Patients with Chronic Myeloid Leukemia Receiving BuCy2 as Preparation for Allotransplantation.
Authors: Edward A. Copelan, Anthony J. Dodds, Brian J. Bolwell, Pamela Ann Crilley, Patrick Elder, Shubham Pant, Matt Kalaycio, Ronald Sobecks, David Topolsky, Ian Nivison-Smith, Belinda R. Avalos, Jeffrey Szer
Journal: Blood (2006)
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City.
Authors: H. C. Arce Salinas, R. Ramirez-Morales, C. Aguila, A. Alvarado Miranda, J. Santamaria-Galicia, D. Cantu
Journal: Journal of Clinical Oncology (2011)

134 Background: Breast cancer in older women has a tendency to increase its incidence; the prevalence and their clinical course are not reported. This group of patients is usually considered to be fragile; they receive dose levels of chemotherapy below standards. Objective: To compare the association of dose intensity with complete pathological response (cPR) in older women. Methods: This is a retrospective analysis of patients treated with neoadjuvant anthracyclines, taxanes, or combination regimen from 2005 to 2008. Pathologic response was evaluated in the surgical specimen. Results: We analyzed 801 cases, 694 (86.6%) patients were younger than 65 years-old and 107 (13.3%) were older than 65 years-old. Clinical stage, histological type and HER2 status were similar in both groups. High-grade lesions were more common in the younger group (61% vs. 41% p&gt;0.05). ER+/PR+ were more frequent for the group &gt;65 years-old (57.5/47% vs. 79.5/50%) p=NS. Triple-negative were 154 cases (22%) for younger patients and 14 cases (13%) for elderly women (p=0.02). Optimal dose intensity was above 80% of planned dose. For anthracycline-based regimen, older patients had more dose reduction (27.8%) in comparison to the younger group 2.1% (p= 0.00001), for the taxane regimen dose intensity was less than the standard in 8.8% of young population vs. 17.6% for older women (p = 0.03). The rate of cPR in younger patients was 20.3% vs. 11.1% in the older group (p&lt;0.001). Toxicity profile was statistically similar in both groups. Conclusions: Breast cancer has the same presentation in younger and in older patients. Older patients receive less dose intense chemotherapy. This is associated with a lesser rate of cPR. Therefore, older patient should be treated with full doses taking into account the toxicity profile of the chemotherapeutic regimens as well as the physical and medical conditions of the patient.
Use of a meal replacement weight loss intervention in survivors of ER/PR-negative breast cancer.
Authors: B. Milliron, J. O. Hopkins, A. Fulmer, L. D. Case, M. Vitolins
Journal: Journal of Clinical Oncology (2011)

166 Background: The detrimental relationship between body mass index and recurrence has been more pronounced among women with estrogen receptor/progesterone receptor (ER/PR)-negative breast cancer. Although studies have reported that soy-based meal replacements can favorably impact weight and other metabolic risk factors, meal replacement strategies have not been tested in this population. The objectives of this pilot study were to determine the feasibility of a soy-based meal replacement intervention, to measure changes in anthropometrics and biomarkers, and to measure changes in health-related quality of life (QOL). Methods: The 3-month intervention included education sessions, meal replacement products, meal plans, and physical activity promotion. Anthropometrics, blood samples, and questionnaire data were collected. Paired t-tests assessed changes over time in continuous measures. Weights were measured weekly and a mixed model regression analysis assessed change in weight over time. Results: Nineteen women participated in the study (mean age 59 years). When comparing pre and post intervention weights, women lost ~7.5 ± 4.9 kg (p &lt; 0.001) and had significant improvements in health-related QOL. Women lost 7.5% of their baseline weight which exceeded our study goal (5% reduction). There were significant reductions in waist circumference (-7.5 ± 4.9 cm, p = 0.001), % fat mass (-9.4 ± 8.3, p &lt; 0.001), total cholesterol (p = 0.026), and triglycerides (p = 0.002). Conclusions: The use of this weight loss approach was well-received by the study participants. We are currently evaluating whether this approach had a long-term impact on the weight status and quality of life among the study participants. [Table: see text]
Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
Authors: Françoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, Loïc Campion, Anne Moreau, Isabelle Soubeyran, Steven Le Gouill, Olivier Tournilhac, Etienne Daguindau, Henry Jardel, Nadine Morineau, Krimo Bouabdallah, Emmanuel Gyan, Marie-Pierre Moles, Remy Gressin, Christian Berthou, Sophie Sadot, Philippe Moreau, Bénédicte Deau, Caroline Bodet-Milin, Anne-Laure Cazeau, Etienne Garin, Pierre-Yves Salaun, Jean-Philippe Vuillez, Valérie Gouilleux-Gruart, Jacques Barbet, William A Wegener, David M Goldenberg, Thierry Lamy, Pierre Soubeyran
Journal: The Lancet Haematology (2016)
Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients
Authors: Jun Zhang, Mengmeng Jia, Lihua Zuo, Na Li, Yonggang Luo, Zhi Sun, Xiaojian Zhang, Zhenfeng Zhu
Journal: Acta Pharmaceutica Sinica B (2016)

The aim of the research was to investigate the pharmacokinetics (PK) of enteric-coated mycophenolate sodium (EC-MPS) by quantification of the active metabolite of mycophenolic acid (MPA) after multiple escalating oral doses in Han kidney transplant recipients. A total of 28 Han postoperative kidney transplant recipients were given a multiple-dose of 540, 720 or 900 mg of EC-MPS two times a day in combination with tacrolimus for 6 days. Blood specimens were collected at each time point from 0 to 12 h after EC-MPS administration. MPA plasma concentrations were measured by UPLC-UV. The relationship between the EC-MPS dose and its PK parameters was assessed. In the range from 540 to 900 mg, Cmax and AUC0-12h did not increase with dose escalation. The AUC0-12h, Cmax, C0 and Tmax for the 540 720 and 900 mg doses were not significantly different, respectively (P >0.05). AUC0-12 h and Cmax were increased less than proportionally with increasing EC-MPS dose levels. Inter-individual variability in AUC0-12h, Cmax and C0 were considerable. Nonlinear PK relationships were found from the doses of 540-900 mg of EC-MPS.
What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis
Authors: Laureen Ribassin-Majed, Sophie Marguet, Anne W.M. Lee, Wai Tong Ng, Jun Ma, Anthony T.C. Chan, Pei-Yu Huang, Guopei Zhu, Daniel T.T. Chua, Yong Chen, Hai-Qiang Mai, Dora L.W. Kwong, Shie-Lee Cheah, James Moon, Yuk Tung, Kwan-Hwa Chi, George Fountzilas, Jean Bourhis, Jean Pierre Pignon, Pierre Blanchard
Journal: Journal of Clinical Oncology (2017)

Purpose The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial. The individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments. Methods All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixed- and random-effects frequentist network meta-analysis models were applied. Results The three treatments with the highest probability of benefit on overall survival (OS) were CRT-AC, followed by CRT and IC-CRT, with respective hazard ratios (HRs [95% CIs]) compared with RT alone of 0.65 (0.56 to 0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS, progression-free survival (PFS), locoregional control, and distant control (DC) were, respectively, 0.85 (0.68 to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and the best for DC. CRT never ranked first. HRs of CRT compared with IC-CRT for OS, PFS, locoregional control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55 (0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity. Conclusion The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points. The addition of IC to CRT achieved the highest effect on DC.
Helical tomotherapy and concurrent gemcitabine-based chemotherapy for locally advanced pancreatic cancer.
Authors: Jinsil Seong, Jisuk Chang, Siyoung Song, Woong Keum
Journal: Journal of Clinical Oncology (2012)

318 Background: To improve poor therapeutic outcome of current practice of chemoradiotherapy (CRT), high dose helical tomotherapy (HT) with concurrent full-dose chemotherapy has been performed on patients with locally advanced pancreatic cancer (LAPC), and the results were analyzed. Methods: We retrospectively reviewed 39 patients with LAPC treated with radiotherapy using HT (median, 58.4 Gy; range, 50.8-59.9 Gy) and concomitant chemotherapy between May 2006 and May 2009. Radiotherapy was directed to the primary tumor with a 0.5 cm margin without prophylactic nodal coverage. Twenty nine patients (79%) received full-dose (1000 mg/m 2 ) gemcitabine based chemotherapy during HT. After completion of CRT, maintenance chemotherapy was administered to 37 patients (95%). Results: The median follow-up was 15.5 months (range 3.4-43.9) for the entire cohort, and 22.5 months (range 12.0-43.9) for surviving patients. The 1- and 2-year local progression-free survival rates were 82.1% and 77.3%, respectively. Eight patients (20%) were converted to resectable status, including one with a pathologic complete response. The median overall survival and progression-free survival were 21.2 and 14.0 months, respectively. Acute toxicities were acceptable with no gastrointestinal (GI) toxicity higher than grade 3. Severe late GI toxicity (≥ Grade 3) occurred in 10 patients (26%); one treatment related death due to GI bleeding was observed. Conclusions: High-dose helical tomotherapy with concurrent full-dose chemotherapy resulted in improved local control and long-term survival in patients with LAPC. Future studies are needed to widen the therapeutic window by minimizing late GI toxicity.
Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Authors: Rami S. Komrokji, Mikkael A. Sekeres, John Barnard, Najla Alali, Amy E. DeZern, Eric Padron, David Sallman, Jeffrey E. Lancet, Gail J. Roboz, Jaime Fensterl, Guillermo Garcia-Manero, David P. Steensma, Alan F List
Journal: Blood (2016)
Deferasirox (Exjade®, ICL670) Demonstrates Dose-Related Effects on Body Iron Levels Related to Transfusional Iron Intake in Transfusion-Dependent Anemia.
Authors: P. Greenberg, G. Dine, A. Ganser, G. Verhoef, L. DeBusscher, G. Quarta, P. Zachée, G. Alimena, M. Jeng, G. Tchernia, I. Gathmann, D. Alberti, B. Rabault
Journal: Blood (2005)
Defining survival for patients with breast cancer with brain metastases.
Authors: N. P. Pathe, S. Khalid, C. Khan, F. D. Atem, M. G. Trombetta, C. E. Geyer
Journal: Journal of Clinical Oncology (2011)

258 Background: Brain metastases account for 100,000 to 170,000 cases per year in the U.S, the bulk being from breast and lung primaries. About 10-15% of breast cancer patients develop brain metastases and historically, their survival has been poor. Introduction of novel chemotherapeutic and biologic agents and newer radiation techniques in the past decade has led to better control of systemic disease raising the possibility of increasing incidence of brain metastases as well as better control of CNS disease. The aim of this study was to determine the survival of breast cancer patients with brain metastases in our practice in the last 10 years. Methods: This study was a retrospective chart analysis and we analyzed the charts of 18 patients with breast cancer who had developed brain metastases. The parameters analyzed included patient age at diagnosis of breast cancer and at development of brain metastases, receptor status and various treatment modalities used to control local as well as Metastatic disease. Results: The median survival time after adjusting for age at diagnosis of breast cancer, age at diagnosis of brain metastases and the number of brain metastases was 55 months. The time to death was analyzed using Cox proportional hazard model, adjusting for age and number of brain metastases. Age at diagnosis of breast cancer was significant with a p-value of 0.007 and the number of brain metastases was not significant with a p-value of 0.55. Using the Log Rank test, median survival for Her2neu positive patients was 71 months and for Her2neu negative patients was 58 months with a non-significant p value of 0.86. Review of treatment modalities revealed that six patients underwent surgical removal of metastases and 12 patients received WBRT. Average number of systemic treatments used was 6.7 including chemotherapeutic, biological and hormonal agents. Conclusions: In our practice, the overall survival of breast cancer patients with brain metastases was found to be 55 months after adjusting for age at diagnosis of breast cancer, age at diagnosis of brain metastases and number of brain metastases. Overall survival did not vary significantly with the number of brain metastases and Her2neu receptor status.
Prevalence of 46/1 JAK2 Haplotype in Patients with Budd-Chiari Syndrome with and without JAK2V617F and TET2 Mutations.
Authors: Nicholas C Lea, Lara N Roberts, Raj K Patel, Rachel Westbrook, Michael A Heneghan, Azim M Mohamedali, Alex E Smith, Atiyeh Abdallah, Nigel Westwood, Trisevgeni Kontou, Deborah Yallop, Roopen Arya, Antonio Pagliuca, Joop Gaken, Nigel D Heaton, Ghulam J Mufti
Journal: Blood (2009)